Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Zibotentan + dapagliflozin versus dapagliflozin in chronic kidney disease with high proteinuria
2023-504124-26-00Phase 3Authorised
- Sponsor
- AstraZeneca
- Start
- Apr 2024
- Modality
- Small Molecules
- Countries
- 31
01
Overview
Phase 3, randomised, double-blind trial in chronic kidney disease (CKD) comparing Zibotentan + dapagliflozin fixed-dose combination with Dapagliflozin alone (2 arms). Primary endpoint: Change in eGFR from baseline to Month 24. Planned start Apr 2024; status: authorised.
02
Drugs
zibotentandapagliflozin
03
Conditions
chronic kidney disease (CKD)
Beyond the preview
Go deeper on 2023-504124-26-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2023-504124-26-00.